NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: bevacizumab
Drug: docetaxel
Other: laboratory biomarker analysis

First Posted Date: 2003-03-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00055861

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Squamous Cell Carcinoma of the Oropharynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Interventions: Biological: bevacizumab
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-03-07

Last Posted Date: 2018-10-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00055913

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Phase 2

Completed

Conditions: Localized Unresectable Adult Primary Liver Cancer
Adult Primary Hepatocellular Carcinoma
Recurrent Adult Primary Liver Cancer

Interventions: Biological: bevacizumab

First Posted Date: 2003-03-07

Last Posted Date: 2016-02-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00055692

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Phase 2

Completed

Conditions: HIV Seronegativity
Kaposi's Sarcoma
HIV Infections

Interventions: Biological: Bevacizumab

First Posted Date: 2003-02-21

Last Posted Date: 2017-09-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00055237

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

Phase 2

Completed

Conditions: Pituitary Disease
Thyroid Disease
Healthy

Interventions: Drug: TRH (Thyrotropin Releasing Hormone)

First Posted Date: 2003-02-10

Last Posted Date: 2018-08-08

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 96

Registration Number: NCT00054756

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

Phase 1

Completed

Conditions: Neurofibromatosis Type 1
Precancerous Condition

First Posted Date: 2003-02-06

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00053937

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 12 locations

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: oblimersen sodium
Drug: paclitaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-02-06

Last Posted Date: 2013-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00054548

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Phase 2

Completed

Conditions: Cervical Cancer
Cervical Intraepithelial Neoplasia Grade 3
Human Papilloma Virus Infection

Interventions: Procedure: therapeutic conventional surgery
Biological: HspE7
Other: laboratory biomarker analysis

First Posted Date: 2003-02-06

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT00054041

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Blastic Phase Chronic Myelogenous Leukemia
Childhood Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Relapsing Chronic Myelogenous Leukemia

Interventions: Drug: imatinib mesylate
Drug: decitabine
Other: laboratory biomarker analysis

First Posted Date: 2003-02-06

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00054431

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Phase 1

Completed

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Chronic Myelogenous Leukemia
Childhood Craniopharyngioma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma

Interventions: Drug: romidepsin

First Posted Date: 2003-02-06

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00053963

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Home Terms & Conditions Privacy Policy